NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
AstraZeneca
National Institutes of Health Clinical Center (CC)
AstraZeneca
AGO Study Group
Eli Lilly and Company